Who
Kristina Burow
Director
Company insider
Files Form 4 as: Director and 10% owner, Scholar Rock Holding; Director and 10% owner, Neumora Therapeutics; Director and 10% owner, Metsera; Director and 10% owner, Boundless Bio; 10% owner, Sana Biotechnology; Director, Gossamer Bio; Director, Beam Therapeutics; 10% owner, Erasca.
In numbers
- Trades disclosed
- 276
- Buys
- 23
- Sells
- 7
- Bought
- $122.0M
- Sold
- $6.4M
- Companies
- 13
- Companies where not an officer
- 13
- First trade
- 14 May 2013
- Last trade
- 1 Jul 2026
- Last filed
- 6 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Jul 2026filed 6 Jul 2026 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Sold | $113K2,105 at $53.49 | filing |
| 1 Jul 2026filed 6 Jul 2026 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Sold | $51K948 at $54.28 | filing |
| 1 Jul 2026filed 6 Jul 2026 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Sold | $113K2,105 at $53.49 | filing |
| 1 Jul 2026filed 6 Jul 2026 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Sold | $51K948 at $54.28 | filing |
| 4 Jun 2026filed 8 Jun 2026 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Code A | —6,839 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | SRRK Scholar Rock Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,310 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | SRRK Scholar Rock Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,310 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Code A | —6,839 at $0.00 | filing |
| 27 May 2026filed 29 May 2026 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —80,000 at $0.00 | filing |
| 27 May 2026filed 29 May 2026 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —80,000 at $0.00 | filing |
| 23 Apr 2026filed 24 Apr 2026 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Code M | $209K7,800 at $26.78 | filing |
| 23 Apr 2026filed 24 Apr 2026 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Code M | $133K28,000 at $4.75 | filing |
| 23 Apr 2026filed 24 Apr 2026 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Code M | $328K36,000 at $9.11 | filing |
| 23 Apr 2026filed 24 Apr 2026 | SRRK Scholar Rock Holdingoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,800 at $0.00 | filing |
| 23 Apr 2026filed 24 Apr 2026 | SRRK Scholar Rock Holdingoption or derivative · Biotechnology | SEC FORM 4 Code M | —28,000 at $0.00 | filing |
| 23 Apr 2026filed 24 Apr 2026 | SRRK Scholar Rock Holdingoption or derivative · Biotechnology | SEC FORM 4 Code M | —36,000 at $0.00 | filing |
| 23 Apr 2026filed 24 Apr 2026 | SRRK Scholar Rock Holdingoption or derivative · Biotechnology | SEC FORM 4 Code M | —18,000 at $0.00 | filing |
| 23 Apr 2026filed 24 Apr 2026 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Code M | $150K18,000 at $8.36 | filing |
| 23 Apr 2026filed 24 Apr 2026 | SRRK Scholar Rock Holdingoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,800 at $0.00 | filing |
| 23 Apr 2026filed 24 Apr 2026 | SRRK Scholar Rock Holdingoption or derivative · Biotechnology | SEC FORM 4 Code M | —28,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.